Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

Carboplatin 18Radiotherapy 10Cisplatin 10Pemetrexed 8Paclitaxel 8durvalumab 6Magnetic Resonance Spectroscopy 6Gemcitabine 6Radiosurgery 5Nivolumab 5Etoposide 5pembrolizumab 4atezolizumab 4Surveys and Questionnaires 4Radiation 4Erlotinib Hydrochloride 4Docetaxel 4Taxes 3Standard of Care 3Specimen Handling 3Platinum 3Cetuximab 3Bronchoscopy 3Biopsy 3Bevacizumab 31,2-diaminocyclohexaneplatinum II citrate 3sapanisertib 2etoposide phosphate 2capmatinib 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lung Neoplasms × auricularum × Clear all
NCT04267913 2020-11-20

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡